Topical sodium cromoglicate relieves allergen- and histamine-induced dermal pruritus. 2010

R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
Department of Dermatology and Allergy, Allergie-Centrum-Charité, Charité- Universitätsmedizin Berlin, Berlin, Germany.

BACKGROUND Sodium cromoglicate (SCG) has long been used in the management of allergic diseases, including as an ointment for atopic dermatitis. Although mast cell stabilization was initially considered as its mechanism of action, anti-inflammatory actions and modulation of sensory nerve function have also been suggested. OBJECTIVE To investigate the mechanism(s) by which SCG relieves allergen- and histamine-induced dermal inflammation by assessing its effects on pruritus, flare, skin temperature and weal volume. METHODS Aqueous cream containing 0.2%, 1% or 4% SCG or no SCG (placebo) was applied in a randomized single-blind manner to four areas on each forearm (two sites per arm) and covered with an occlusive dressing. One hour later, skin-prick tests were performed in 20 allergic subjects with allergens to which they had previously shown sensitization, and in 40 nonallergic subjects with codeine (9 mg mL(-1), 20 subjects) and histamine (10 mg mL(-1), 20 subjects). Weal volume, skin temperature increase, erythema area and pruritus intensity were assessed at 0, 5, 10 and 15 min. RESULTS SCG significantly (P < 0.05 to P < 0.001) reduced pruritus induced by all stimuli, with 4% SCG being most effective. Significant (P < 0.05 to P < 0.01) reductions of erythema area were also seen but there was no inhibition of weal volume or temperature increase. CONCLUSIONS SCG is effective in reducing pruritus but has no effect on weals, supporting the proposition that, in the skin, SCG inhibits sensory C-fibre nerve activation rather than preventing mast cell degranulation. We suggest that topical SCG treatment, delivered in an appropriate vehicle, may be beneficial for symptomatic relief of pruritus in patients with cutaneous mastocytosis and other pruritic dermatoses.

UI MeSH Term Description Entries
D008297 Male Males
D011537 Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief. Itching,Pruritis
D004205 Cromolyn Sodium A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack. Disodium Cromoglycate,Sodium Cromoglycate,Aarane,Bicromat Spray,Cromoglicic Acid,Cromoglycate,Cromoglycic Acid,Cromolyn,FPL-670,Intal,Lomudal,Nalcrom,Nasalcrom,Opticrom,Vicrom,Acid, Cromoglicic,Acid, Cromoglycic,Cromoglycate, Disodium,Cromoglycate, Sodium,FPL 670,FPL670
D005260 Female Females
D006632 Histamine An amine derived by enzymatic decarboxylation of HISTIDINE. It is a powerful stimulant of gastric secretion, a constrictor of bronchial smooth muscle, a vasodilator, and also a centrally acting neurotransmitter. Ceplene,Histamine Dihydrochloride,Histamine Hydrochloride,Peremin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000279 Administration, Cutaneous The application of suitable drug dosage forms to the skin for either local or systemic effects. Cutaneous Drug Administration,Dermal Drug Administration,Drug Administration, Dermal,Percutaneous Administration,Skin Drug Administration,Transcutaneous Administration,Transdermal Administration,Administration, Dermal,Administration, Transcutaneous,Administration, Transdermal,Cutaneous Administration,Cutaneous Administration, Drug,Dermal Administration,Drug Administration, Cutaneous,Skin Administration, Drug,Administration, Cutaneous Drug,Administration, Dermal Drug,Administration, Percutaneous,Administrations, Cutaneous,Administrations, Cutaneous Drug,Administrations, Dermal,Administrations, Dermal Drug,Administrations, Percutaneous,Administrations, Transcutaneous,Administrations, Transdermal,Cutaneous Administrations,Cutaneous Administrations, Drug,Cutaneous Drug Administrations,Dermal Administrations,Dermal Drug Administrations,Drug Administrations, Cutaneous,Drug Administrations, Dermal,Drug Skin Administrations,Percutaneous Administrations,Skin Administrations, Drug,Skin Drug Administrations,Transcutaneous Administrations,Transdermal Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000485 Allergens Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE). Allergen
D012720 Severity of Illness Index Levels within a diagnostic group which are established by various measurement criteria applied to the seriousness of a patient's disorder. Illness Index Severities,Illness Index Severity

Related Publications

R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
November 1981, Journal of the American Academy of Dermatology,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
February 2013, The Journal of pharmacology and experimental therapeutics,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
January 2012, International journal of pharmaceutical compounding,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
January 1985, Dermatologica,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
December 2018, Polish journal of veterinary sciences,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
March 2011, BMC research notes,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
June 1983, Singapore medical journal,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
September 2011, European journal of pharmacology,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
June 2011, BMJ case reports,
R Vieira Dos Santos, and M Magerl, and P Martus, and T Zuberbier, and M K Church, and L Escribano, and M Maurer
October 2006, Allergy,
Copied contents to your clipboard!